64 related articles for article (PubMed ID: 12404879)
1. Synthesis and beta 1-, beta 2-adrenergic receptor binding studies of 4-acylamino-substituted phenoxypropanolamine and 5-acylamino-substituted naphthyloxypropanolamine derivatives.
Jindal DP; Coumar MS; Bruni G; Massarelli P
Arzneimittelforschung; 2002; 52(9):654-63. PubMed ID: 12404879
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the binding affinity of some newly synthesized phenylethanolamine and phenoxypropanolamine compounds at recombinant human beta- and alpha1-adrenoceptor subtypes.
Ahmed M; Hanaoka Y; Kiso T; Kakita T; Ohtsubo Y; Muramatsu I; Nagatomo T
J Pharm Pharmacol; 2005 Jan; 57(1):75-81. PubMed ID: 15638996
[TBL] [Abstract][Full Text] [Related]
3. Different sensitivity of beta 1- and beta 2-adrenergic receptors towards cyanogen bromide.
Severne Y; Vauquelin G
Arch Int Pharmacodyn Ther; 1988; 292():122-30. PubMed ID: 2840038
[TBL] [Abstract][Full Text] [Related]
4. Selective alteration in high affinity agonist binding: a mechanism of beta-adrenergic receptor desensitization.
Wessels MR; Mullikin D; Lefkowitz RJ
Mol Pharmacol; 1979 Jul; 16(1):10-20. PubMed ID: 39240
[No Abstract] [Full Text] [Related]
5. In vitro measurement of the beta-adrenergic blocking properties of ORF 12592, the 5-hydroxy analog of propranolol.
Greenslade FC; Newquist KL
Arch Int Pharmacodyn Ther; 1978 Jun; 233(2):270-80. PubMed ID: 28704
[TBL] [Abstract][Full Text] [Related]
6. Interactions of agonists and antagonists with beta-adrenergic receptors.
Molinoff PB; Weiland GA; Heidenreich KA; Pittman RN; Minneman KP
Adv Cyclic Nucleotide Res; 1981; 14():51-67. PubMed ID: 6116391
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, beta-adrenergic blocking activity and beta-receptor binding affinities of 1-substituted-3-(2-isopropyl-5-methyl-phenoxy)-propan-2-ol oxalates.
Jindal DP; Coumar MS; Nandakumar K; Bodhankar SL; Purohit PG; Mahadik KR; Bruni G; Collavoli E; Massarelli P
Farmaco; 2003 Aug; 58(8):557-62. PubMed ID: 12875885
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and adrenergic activity of a new series of N-aryl dicyclopropyl ketone oxime ethers: SAR and stereochemical aspects.
Blanc M; Tamir A; Aubriot S; Michel MC; Bouzoubaa M; Leclerc G; Demenge P
J Med Chem; 1998 May; 41(10):1613-8. PubMed ID: 9572886
[TBL] [Abstract][Full Text] [Related]
9. Studies on the receptor profile of bisoprolol.
Klockow M; Greiner HE; Haase A; Schmitges CJ; Seyfried C
Arzneimittelforschung; 1986 Feb; 36(2):197-200. PubMed ID: 2870719
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationship studies of phenoxypropanolamine derivatives for beta 3-adrenergic activity.
Ahmed M; Hanaoka Y; Nagatomo T
Nihon Yakurigaku Zasshi; 2002 Nov; 120(1):112P-113P. PubMed ID: 12491799
[TBL] [Abstract][Full Text] [Related]
11. Visualization of the turkey erythrocyte beta-adrenergic receptor.
Durieu-Trautmann O; Delavier-Klutchko C; Vauquelin G; Strosberg AD
J Supramol Struct; 1980; 13(4):411-9. PubMed ID: 6112288
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of some xanthone derivatives for anti-arrhythmic, hypotensive properties and their affinity for adrenergic receptors.
Marona H; Szkaradek N; Kubacka M; Bednarski M; Filipek B; Cegla M; Szneler E
Arch Pharm (Weinheim); 2008 Feb; 341(2):90-8. PubMed ID: 18240129
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of some aroxyethylamine derivatives for hypotensive properties and their affinities for adrenergic receptors.
Maciag D; Filipek B; Czekaj T; Marona H; Nowak G
Pharmazie; 2003 Dec; 58(12):899-905. PubMed ID: 14703970
[TBL] [Abstract][Full Text] [Related]
14. Effects of celiprolol (REV 5320), a new cardioselective beta-adrenoceptor antagonist, on in vitro adenylate cyclase, alpha- and beta-adrenergic receptor binding and lipolysis.
Van Inwegen RG; Khandwala A; Weinryb I; Pruss TP; Neiss E; Sutherland CA
Arch Int Pharmacodyn Ther; 1984 Nov; 272(1):40-55. PubMed ID: 6151380
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, binding affinity and selectivity of new beta 1- and beta 2-adrenoceptor blockers.
Brizzi V; Francioli M; Brufani M; Filocamo L; Bruni G; Massarelli P
Farmaco; 1999; 54(11-12):713-20. PubMed ID: 10668169
[TBL] [Abstract][Full Text] [Related]
16. Potent and selective human beta(3)-adrenergic receptor antagonists.
Candelore MR; Deng L; Tota L; Guan XM; Amend A; Liu Y; Newbold R; Cascieri MA; Weber AE
J Pharmacol Exp Ther; 1999 Aug; 290(2):649-55. PubMed ID: 10411574
[TBL] [Abstract][Full Text] [Related]
17. Agonist-specific alterations in receptor binding affinity associated with solubilization of turkey erythrocyte membrane beta adrenergic receptors.
Pike LJ; Lefkowitz RJ
Mol Pharmacol; 1978 Mar; 14(2):370-5. PubMed ID: 25377
[No Abstract] [Full Text] [Related]
18. Radioligand binding studies with 3-(4-(2-hydroxy-3-((1, 1-dimethylethyl)-amino)-propoxy)-phenyl)-7-methoxy-2-methyl- 1(2H)-isoquinolinone (HI-42), a new cardioselective beta-adrenoceptor blocker with long-lasting effects in vivo.
Jackisch R; Lederle M; Hertting G
Arzneimittelforschung; 1985; 35(1A):237-40. PubMed ID: 2859028
[TBL] [Abstract][Full Text] [Related]
19. Interactions of radiolabelled ligands with specific receptors: an analysis.
Manukhin BN; Nesterova LA; Smurova EA; Kichikulova TP
Membr Cell Biol; 2000; 13(5):667-85. PubMed ID: 10987390
[TBL] [Abstract][Full Text] [Related]
20. Distinctions in beta-adrenergic receptor interactions with the magnesium-guanine nucleotide coupling proteins in turkey erythrocyte and S49 lymphoma membranes.
Vauquelin G; Cech SY; André C; Strosberg AD; Maguire ME
J Cyclic Nucleotide Res; 1982; 8(3):149-62. PubMed ID: 6300206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
